Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.95)
# 2,854
Out of 4,873 analysts
60
Total ratings
42.42%
Success rate
-8.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Overweight | $285 → $300 | $282.50 | +6.19% | 6 | May 29, 2025 | |
| OMCL Omnicell | Maintains: Overweight | $35 → $37 | $28.64 | +29.19% | 16 | May 23, 2025 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $10 → $8 | $7.86 | +1.85% | 3 | May 8, 2025 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $8 → $7 | $5.02 | +39.44% | 8 | Apr 29, 2025 | |
| HQY HealthEquity | Maintains: Overweight | $110 → $125 | $104.44 | +19.69% | 9 | Feb 26, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $43 → $55 | $61.05 | -9.91% | 10 | Feb 7, 2025 | |
| HCAT Health Catalyst | Maintains: Overweight | $13 → $10 | $3.73 | +168.10% | 5 | Jan 21, 2025 | |
| AMWL American Well | Upgrades: Overweight | $15 | $7.55 | +98.68% | 3 | Jan 13, 2025 |
Veeva Systems
May 29, 2025
Maintains: Overweight
Price Target: $285 → $300
Current: $282.50
Upside: +6.19%
Omnicell
May 23, 2025
Maintains: Overweight
Price Target: $35 → $37
Current: $28.64
Upside: +29.19%
Teladoc Health
May 8, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $7.86
Upside: +1.85%
GoodRx Holdings
Apr 29, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $5.02
Upside: +39.44%
HealthEquity
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $104.44
Upside: +19.69%
Doximity
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $43 → $55
Current: $61.05
Upside: -9.91%
Health Catalyst
Jan 21, 2025
Maintains: Overweight
Price Target: $13 → $10
Current: $3.73
Upside: +168.10%
American Well
Jan 13, 2025
Upgrades: Overweight
Price Target: $15
Current: $7.55
Upside: +98.68%